American Vietnamese Biotech

American Vietnamese Biotech FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of American Vietnamese Biotech (AMV.VN) as of Oct 17, 2026 is -5,616.30 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -1,355.10 % — a change of 314.46% (lower).

FCF Conversion

-5,616.30 %

YoY

314.46%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of American Vietnamese Biotech is 2024 -5,616.30 % . FCF Conversion Rate (FCF/EBITDA) of American Vietnamese Biotech was 2023 -1,355.10 % . It decreases by 314.46% lower compared to the previous year.

The American Vietnamese Biotech FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
-741.28 VND
Jan 1, 2018
50.51 VND
Jan 1, 2019
-41.95 VND
Jan 1, 2020
74.93 VND
Jan 1, 2021
-790.37 VND
Jan 1, 2022
-653.80 VND
Jan 1, 2023
-1,355.10 VND
Jan 1, 2024
-5,616.30 VND
The American Vietnamese Biotech FCF Conversion history
YEARFCF ConversionYoY
-5,616.30 %+314.46%
-1,355.10 %+107.27%
-653.80 %-17.28%
-790.37 %-1,154.79%
74.93 %-278.63%
-41.95 %-183.05%
50.51 %-106.81%
-741.28 %-357.00%
288.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

American Vietnamese Biotech Stock analysis

What does American Vietnamese Biotech do? American Vietnamese Biotech Inc, headquartered in Ho Chi Minh City, Vietnam, operates in the Health Care sector. The company manufactures and distributes high-tech medical diagnostics devices, equipment, medicines, vaccines, biological products, rapid diagnostic tests, and ELISA kits. It also trades medical equipment and tools, produces cosmetic, soap, detergent, and cleaning products, and engages in real estate trading, financial investments, and plastic product manufacturing. Listed on December 20, 2009, the company had one wholly owned subsidiary as of 2012. American Vietnamese Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about American Vietnamese Biotech stock

FCF Conversion Rate (FCF/EBITDA) of American Vietnamese Biotech is -5,616.30 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of American Vietnamese Biotech changed from -1,355.10 % to -5,616.30 %, representing a 314.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) American Vietnamese Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s American Vietnamese Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — American Vietnamese Biotech

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — American Vietnamese Biotech